ARA290 vs BPC-157
ARA290, also called cibinetide, is an 11-amino-acid non-erythropoietic peptide engineered from the helix B domain of erythropoietin and designed to activate the innate repair receptor without stimulating red cell production. BPC-157 is a synthetic pentadecapeptide derived from a fragment of a protein found in gastric juice, with a preclinical literature concentrated in rodent tendon, ligament, muscle and gastrointestinal injury. The pair is set side by side in vendor material because both are promoted for nerve and soft-tissue repair, and often promoted together as a combination. No study has administered both, in the same animals, the same cells or the same patients, and no combination of the two has been tested in any published experiment. Two recent reviews name and describe both, and neither dosed anything. Their separate evidence bases point in opposite directions on quality: ARA290 has completed randomised human trials in indications unrelated to musculoskeletal recovery, while BPC-157 has a far larger animal literature and no completed randomised trial at all.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has tested ARA290 and BPC-157 against each other, given them together, or measured them under a shared protocol, in any model. Searches of PubMed and Europe PMC using the trade name, the international non-proprietary name cibinetide, the helix B surface peptide description and the pentadecapeptide BPC designation returned only two records that engage both, and both are narrative reviews that administered nothing. A 2026 review of regenerative peptides in chronic pain management covered collagen peptides, BPC-157, thymosin beta-4, TB-500, GHK-Cu, growth hormone-related peptides and cibinetide within one framework, summarising proposed mechanisms, evidence and regulatory status for each and stating that most remain unapproved by the US Food and Drug Administration. A 2026 review of peptide approaches to wound pain and healing described the two separately at greater length: it reported that ARA290 counteracted capsaicin-induced mechanical hypersensitivity after subcutaneous administration, alleviated mechanical and cold allodynia in the spared nerve injury model in rats and mice, and improved microvascular perfusion in a mouse burn model, while BPC-157 applied topically as a hydrogel to alkali-burned rat skin accelerated healing but produced inconclusive analgesic results, showing no effect in an incisional model of acute pain. Any comparison between the two is therefore assembled from unrelated experiments with different injuries, species and endpoints.
The 2 publications that cover both
- 01Review2026
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management
Luansritisakul C, et al. · Curr Pain Headache Rep · narrative review of regenerative peptides relevant to chronic pain, covering collagen peptides, BPC-157, thymosin beta-4, TB-500, GHK-Cu, growth hormone-related peptides and cibinetide (ARA-290)
This is the only PubMed record that names both compounds in its abstract. The review summarised proposed mechanisms of action, potential clinical applications, preclinical and clinical evidence, safety profiles and regulatory status for each peptide, and reported that evidence for regenerative peptides in chronic pain management remains limited. The authors stated that most of these therapies remain unapproved by the US Food and Drug Administration. Nothing was administered.
- 02Review2026
Peptide-Based Approaches for Pain Relief and Healing in Wounds
Kołodyńska K, et al. · Int J Mol Sci · narrative review of topically applied and locally acting peptides with analgesic, anti-inflammatory and regenerative activity in painful and chronic wounds
The review treated the two peptides in separate sections and drew no comparison between them. For ARA290 it reported relief of capsaicin-induced mechanical hypersensitivity, alleviation of mechanical and cold allodynia in the spared nerve injury model in rats and mice, regeneration of small autonomic nerve fibres in diabetic neuropathy, improved microvascular perfusion in a mouse burn model via upregulated antioxidant response, and improved healing in a streptozotocin-induced mouse model of diabetic foot ulcer. For BPC-157 it reported dose-dependent acceleration of healing in alkali-burned rat skin with better granulation tissue formation and re-epithelialisation, but described the analgesic evidence as inconclusive, noting no analgesic effect in an incisional model of acute pain alongside a reported clinical improvement rate after intra-articular administration in knee pain.
Side by side.
| ARA290 | BPC-157 | |
|---|---|---|
| Evidence maturity | Early clinical | Preclinical only |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 7 | 8 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | An 11-amino-acid peptide engineered from the tertiary structure of the helix B domain of erythropoietin, designed to retain tissue protection while removing the erythropoietic effect. It carries an international non-proprietary name, cibinetide. | A synthetic 15-amino-acid peptide whose sequence corresponds to a fragment of a protein found in gastric juice. It has no confirmed endogenous circulating counterpart and no international non-proprietary name. |
| Mechanism as described in the literature | Selective activation of the innate repair receptor, described as a heteromer of the erythropoietin receptor and the beta-common receptor (CD131). The mechanism was established by the loss of effect in beta-common receptor knockout mice, and later work reports anti-inflammatory action on macrophages and Schwann cells. | Preclinical work attributes effects to angiogenesis associated with VEGFR2 activation and upregulation, and to modulation of the nitric oxide system, with additional cytoprotective and gut-barrier effects reported in rodents. No receptor for the peptide has been identified. |
| Size and shape of the evidence base | Modest in volume but weighted toward human trials: several completed randomised placebo-controlled phase 2 studies, supported by animal work in nerve injury, cerebral ischemia, cardiac aging and islet transplantation and by cell-culture studies. | Very large in volume but almost entirely preclinical: several hundred rodent studies of tendon, ligament, muscle, gastrointestinal and ischemia-reperfusion injury, with much of the corpus originating from a small number of closely affiliated research groups. |
| Best-characterised finding | A 2011 spared nerve injury study reporting long-term relief of tactile and cold allodynia in rats, with no effect in mice lacking the beta-common receptor, which established the receptor complex as the route of action. | A 2006 rat study reporting healing of a completely transected quadriceps muscle with functional restoration where the untreated defect persisted, alongside a 2010 study reporting improved medial collateral ligament healing after transection. |
| Human data | Completed randomised, placebo-controlled phase 2 trials in sarcoidosis-associated small fibre neuropathy, including a 64-subject 28-day multicentre trial with corneal confocal microscopy endpoints, in type 2 diabetes with painful neuropathy, and in diabetic macular edema. | No completed randomised controlled trial for any indication. The human record consists of two uncontrolled open-label pilot studies and one retrospective chart review, all from the same private clinic, plus one ex vivo study on surgically discarded human arterial tissue. |
| Evidence maturity | Early clinical. Human trials exist and are randomised and controlled, but they are small, short and confined to sarcoidosis, diabetic neuropathy and diabetic macular edema; no phase 3 programme has reported. | Preclinical only. Every controlled result comes from animals or isolated tissue, and 2025 and 2026 systematic and narrative reviews in orthopaedic journals characterised the human evidence as insufficient. |
| Regulatory and anti-doping status | No regulatory approval in any jurisdiction despite more than a decade of phase 2 work, and no reported phase 3 trial. | No approved formulation in any jurisdiction. BPC-157 is listed by name among non-approved substances in class S0 of the World Anti-Doping Agency Prohibited List, so it is prohibited in sport at all times. |
| Basis of most marketing claims | Extrapolation from neuropathy and ophthalmic trial endpoints to musculoskeletal and exercise recovery. No published human study of ARA290 has examined tendon, muscle or exercise-related recovery, which is how it is marketed in this category. | Extrapolation from rodent injury models to human tendon, ligament and muscle repair, and from a small uncontrolled clinical series to general efficacy. No human dose, controlled efficacy result or long-term safety dataset has been published. |
And what it does not.
The two compounds have never been compared, and their evidence bases are so differently shaped that a ranking would say more about which type of evidence is being weighted than about the peptides. ARA290 has the stronger designs: randomised, placebo-controlled phase 2 trials with objective endpoints such as corneal nerve fibre measures. What it does not have is any published human or animal study of tendon, muscle or exercise-related recovery, no approval anywhere, and no reported phase 3 trial after more than a decade. BPC-157 has by far the larger literature on the injuries people actually pair these peptides for, but that literature is rodent work concentrated in a few affiliated groups, with no completed randomised trial, no established human dose and no long-term safety data; it is also prohibited in sport at all times. The claim that the two work synergistically for nerve repair appears in marketing material, not in the published record: no study has administered them together.
Common questions.
- Has any study given ARA290 and BPC-157 together?
No. Searches of PubMed and Europe PMC across the trade name, the international non-proprietary name cibinetide, the helix B surface peptide description and the pentadecapeptide BPC designation returned no experiment in which both were administered, whether separately as comparator arms or combined. The two publications that engage both are narrative reviews that describe each peptide from its own literature. Claims of synergy between them, including for peripheral nerve regeneration, have no published experimental basis.
- Which compound has the stronger human evidence?
ARA290, by study design. It has completed randomised, placebo-controlled phase 2 trials in sarcoidosis-associated small fibre neuropathy, in type 2 diabetes with painful neuropathy and in diabetic macular edema, several with objective endpoints such as corneal nerve fibre measures. BPC-157 has no completed randomised controlled trial for any indication; its human record is two uncontrolled open-label pilot studies and one retrospective chart review, all originating from a single private clinic, with no control group or blinding.
- Why is ARA290 described as non-erythropoietic?
Because it was engineered from the helix B domain of erythropoietin specifically to separate the tissue-protective activity of the parent hormone from its effect on red cell production. Native erythropoietin acts through an erythropoietin receptor homodimer and drives erythropoiesis, which limits its use outside anaemia. ARA290 is described as acting instead on the innate repair receptor, a heteromer of the erythropoietin receptor and the beta-common receptor, and the published rodent work reports tissue protection without the haematopoietic effect.
- Does either peptide have published evidence in nerve injury?
ARA290 does, in animals and in patients. Rodent work reported long-term relief of allodynia after spared nerve injury, dependent on the beta-common receptor, and suppression of inflammasome activation in Schwann cells after sciatic nerve crush; the phase 2 trials measured neuropathic symptoms and corneal nerve fibre density in people. For BPC-157 the published nerve-related material is preclinical and secondary to its tendon, muscle and gastrointestinal literature, and no controlled human nerve study has been published.
- What does the sports and orthopaedic literature say about these two?
It says considerably more about one than the other. Recent orthopaedic and sports medicine reviews cover BPC-157 in detail and conclude that its human evidence is insufficient, that no dose or duration is established and that it is prohibited in sport at all times as a non-approved substance. ARA290 is largely absent from that literature; the located reviews that name it sit in pain medicine and wound healing rather than sports medicine, and none addressed musculoskeletal recovery.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.